Annual report
4078.TEDINET S100TSNK
Period2023-04-01 → 2024-03-31
Filed2024-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥82.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥83.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥80.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥84.9bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥87.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥2.9bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥4.4bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥3.1bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.9bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥8.8bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.0bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.2bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥3.7bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥5.0bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥7.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥6.7bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥2.8bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.5bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥6.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥2.6bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥125.4bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥128.0bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥123.9bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥123.0bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥121.6bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥50.0bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥43.3bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥75.5bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥84.7bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥82.7bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥79.3bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥81.5bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥16.6bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥12.4bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥16.5bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.2bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.2bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥9.1bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥6.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥773m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥6.6bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥7.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥4.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.7bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥8.4bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.3bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥3.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.7bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.7bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥68m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-437.65 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥144.85 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥407.06 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-166.58 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥150.84 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥4,586.92 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,970.11 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,875.69 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,502.33 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,657.04 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 59.3% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.6% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.6% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.4% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | -9.2% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.9% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.7% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | -3.6% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.3% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,999 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 2,013 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 2,024 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 2,009 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 2,003 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥40.9bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥42.8bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥41.1bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥34.4bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥37.0bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥1.0bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥285m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥346m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.1bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥4.8bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥943m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.0bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥5.8bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥2.6bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | −¥7.7bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥1.4bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥4.6bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥4.1bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.6bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥86.2bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥87.8bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥87.6bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥88.8bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥88.7bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥41.1bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥35.0bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥45.1bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥52.8bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥52.6bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥51.6bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥55.5bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥7.6bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥5.9bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-476.02 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.72 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥278.97 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-245.57 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.38 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥70 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥75 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥70 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,779.94 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,259.43 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,253.05 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,064.29 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,297.38 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 52.3% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.1% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.1% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.1% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.5% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | -15.8% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.6% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.9% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | -7.7% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.8% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 17,000,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,000,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,000,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,000,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,000,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 753 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 769 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 773 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 774 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 776 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 57
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥40m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥132m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥1.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥1.1bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | −¥15.1bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥2.2bn |
| Chemicalreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥4.2bn |
| Chemicalreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥4.0bn |
| Chemicalreportable segment | employees | at 2024-03-31 | 1660 pure |
| Chemicalreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥75.0bn |
| Chemicalreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥74.1bn |
| Chemicalreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥878m |
| Chemicalreportable segment | segment assets | at 2024-03-31 | ¥127.4bn |
| Chemicalreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥5.1bn |
| Medicine And Healthcarereportable segment | capex | 2023-04-01 → 2024-03-31 | ¥204m |
| Medicine And Healthcarereportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥248m |
| Medicine And Healthcarereportable segment | employees | at 2024-03-31 | 265 pure |
| Medicine And Healthcarereportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥8.2bn |
| Medicine And Healthcarereportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥8.0bn |
| Medicine And Healthcarereportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥244m |
| Medicine And Healthcarereportable segment | segment assets | at 2024-03-31 | ¥13.2bn |
| Medicine And Healthcarereportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥86m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥4.4bn |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥4.2bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥83.2bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥82.1bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| —segment total | segment assets | at 2024-03-31 | ¥140.6bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥5.2bn |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥64m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥146m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥1.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥1.0bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥13.6bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥2.2bn |
| Chemicalreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥3.3bn |
| Chemicalreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥4.0bn |
| Chemicalreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥76.7bn |
| Chemicalreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥76.0bn |
| Chemicalreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥757m |
| Chemicalreportable segment | segment assets | at 2023-03-31 | ¥100.8bn |
| Chemicalreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥6.4bn |
| Medicine And Healthcarereportable segment | capex | 2022-04-01 → 2023-03-31 | ¥207m |
| Medicine And Healthcarereportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥237m |
| Medicine And Healthcarereportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥8.1bn |
| Medicine And Healthcarereportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥7.9bn |
| Medicine And Healthcarereportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥270m |
| Medicine And Healthcarereportable segment | segment assets | at 2023-03-31 | ¥13.6bn |
| Medicine And Healthcarereportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥272m |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥3.5bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥4.3bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥84.9bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥83.9bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥1.0bn |
| —segment total | segment assets | at 2023-03-31 | ¥114.4bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥6.6bn |
| Chemicalreportable segment | employees | at 2024-03-31 | 679 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,778
| Item | Context | Value | Unit |
|---|---|---|---|
| Total assets (5-year summary) | Prior2YearInstant | 123919000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 128021000000 | JPY |
| Total assets (5-year summary) | CurrentYearInstant | 125445000000 | JPY |
| Net assets per share (5-year summary) | Prior4YearInstant | 4657.04 | |
| Net assets per share (5-year summary) | Prior3YearInstant | 4502.33 | |
| Net assets per share (5-year summary) | Prior2YearInstant | 4875.69 | |
| Net assets per share (5-year summary) | Prior1YearInstant | 4970.11 | |
| Net assets per share (5-year summary) | CurrentYearInstant | 4586.92 | |
| Basic earnings loss per share (5-year summary) | Prior4YearDuration | 150.84 | |
| Basic earnings loss per share (5-year summary) | Prior3YearDuration | -166.58 | |
| Basic earnings loss per share (5-year summary) | Prior2YearDuration | 407.06 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 144.85 | |
| Basic earnings loss per share (5-year summary) | CurrentYearDuration | -437.65 | |
| Diluted earnings per share (5-year summary) | Prior4YearDuration | － | |
| Diluted earnings per share (5-year summary) | Prior3YearDuration | － | |
| Diluted earnings per share (5-year summary) | Prior2YearDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior4YearInstant | 0.644 | |
| Equity to asset ratio (5-year summary) | Prior3YearInstant | 0.616 | |
| Equity to asset ratio (5-year summary) | Prior2YearInstant | 0.636 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.629 | |
| Equity to asset ratio (5-year summary) | CurrentYearInstant | 0.593 | |
| Rate of return on equity (5-year summary) | Prior4YearDuration | 0.033 | |
| Rate of return on equity (5-year summary) | Prior3YearDuration | -0.036 | |
| Rate of return on equity (5-year summary) | Prior2YearDuration | 0.087 | |
| Rate of return on equity (5-year summary) | Prior1YearDuration | 0.029 | |
| Rate of return on equity (5-year summary) | CurrentYearDuration | -0.092 | |
| Price earnings ratio (5-year summary) | Prior4YearDuration | 11.9 | |
| Price earnings ratio (5-year summary) | Prior3YearDuration | -12.6 | |
| Price earnings ratio (5-year summary) | Prior2YearDuration | 4.8 | |
| Price earnings ratio (5-year summary) | Prior1YearDuration | 12.2 | |
| Price earnings ratio (5-year summary) | CurrentYearDuration | -4.4 | |
| Net cash provided by used in operating activities (5-year summary) | Prior4YearDuration | 6454000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior3YearDuration | 7826000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior2YearDuration | 6567000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 773000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYearDuration | 6866000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior4YearDuration | -8424000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior3YearDuration | -7422000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior2YearDuration | -1654000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -2620000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYearDuration | -3963000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior4YearDuration | -68000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior3YearDuration | 1667000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior2YearDuration | -5654000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | 3283000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYearDuration | 1259000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior4YearInstant | 9148000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior3YearInstant | 11153000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |